Annovis Bio, Inc. Loss Submission Form

See If You Qualify For Monetary Reward

Enter your details and we will calculate your loss for you

Submit Transaction Detail Now (Optional)

- OR -

    An attorney-client relationship is not created with the submission of this form, nor an obligation on the part of Levi & Korsinsky or you to file a lead plaintiff motion in this matter . The information you submit is held as confidential. If, in its sole discretion, Levi & Korsinsky believes that you might be an appropriate lead plaintiff candidate, Levi & Korsinsky will contact you to discuss the matter and whether to establish an attorney client relationship. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases. Additionally, by submitting this form, you agree to receive an email providing you with login details for CORE (Compensation Recovery Monitoring System) to help you monitor and track your securities. This is a complimentary service. Thank you for submitting your details to Levi & Korsinsky.

    Review Our Privacy Policy

    FAX: 212-363-7171

    Levi & Korsinsky, LLP announces that a ANVS class action lawsuit has been filed on behalf of investors who purchased Annovis Bio, Inc. (ANVS) securities between May 21, 2021 and July 28, 2021. For more on the ANVS Lawsuit please contact us today.

    According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Annovis’s ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

    If you suffered a loss in you have until October 18, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.